The DOI matches its Crossref record.
Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression: A Multicenter, Double-Blind, Placebo-Controlled Trial
Abstract
OBJECTIVE: Lamotrigine is one of the pharmacologic options for the treatment of bipolar depression but has only been studied as monotherapy. This study compared the acute effects of lamotrigine and placebo as add-on therapy to ongoing treatment with lithium in patients with bipolar depression. METHOD: Outpatients (N = 124) aged 18 years and older with a DSM-IV bipolar I or II disorder and a major depressive episode (Montgomery-Asberg Depression Rating Scale [MADRS] score > or = 18 and Clinical Global Impressions-Bipolar Version [CGI-BP] severity of depression score > or = 4) while receiving lithium treatment (0.6-1.2 mmol/L) were randomly assigned to 8 weeks of double-blind treatment with lamotrigine (titrated to 200 mg/d) or placebo. The primary outcome measure was mean change from baseline in total score on the MADRS at week 8. Secondary outcome measures were response (defined as a reduction of > or = 50% on the MADRS and/or change of depression score on the CGI-BP of "much improved" or "very much improved" compared to baseline) and switch to mania or hypomania (defined as a CGI-BP severity of mania score of at least mildly ill at any visit). Patients were included in the study between August 2002 (Spain started in October 2003) and May 2005. RESULTS: Endpoint mean change from baseline MADRS total score was -15.38 (SE = 1.32) points for lamotrigine and -11.03 (SE = 1.36) points for placebo (t = -2.29, df = 104, p = .024). Significantly more patients responded to lamotrigine than to placebo on the MADRS (51.6% vs. 31.7%, p = .030), but not on the CGI-BP change of depression (64.1% vs. 49.2%, p = .105). Switch to mania or hypomania occurred in 5 patients (7.8%) receiving lamotrigine and 2 patients (3.3%) receiving placebo (p = .441). CONCLUSION: Lamotrigine was found effective and safe as add-on treatment to lithium in the acute treatment of bipolar depression. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00224510.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
“An expert review of the available evidence for treatments of bipolar II disorder (BDII) and recommendations based on those findings are presented in Section 6.”
BackgroundInfluentialSelf-citationGoodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Self-citationYatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Self-citationMalhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
Carvalho, A. F., Firth, J., & Vieta, E. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1906193 · Cited by 562
Self-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
Self-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
“An investigator initiated, double-blind, placebo-controlled study found a signifi cant improvement in depression related outcomes, including MADRS score reduction and response/remission rates, in patients receiving adjunctive lamotrigine (van der Loos et al. 2009).”
BackgroundSelf-citationDiagnosis and Treatment of Bipolar Disorder: A Review
Nierenberg, A. A., Agustini, B., Köhler-Forsberg, O., Cusin, C., Katz, D., Sylvia, L. G., Peters, A., & Berk, M. (2023) · JAMA · doi:10.1001/jama.2023.18588 · Cited by 395
Berk, M., Dean, O., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B. S., Kohlmann, K., Jeavons, S., Hewitt, K., Allwang, C., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.06.005 · Cited by 181
Daban, C., Martinez-Aran, A., Cruz, N., & Vieta, E. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.02.012 · Cited by 163
Self-citationBahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Taylor, D. M., Cornelius, V., Smith, L., & Young, A. H. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12343 · Cited by 122
Geddes, J. R., Gardiner, A., Rendell, J., Voysey, M., Tunbridge, E., Hinds, C., Yu, L.-M., Hainsworth, J., Attenburrow, M.-J., Simon, J., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00450-2 · Cited by 112
Carlson, B. X., Ketter, T. A., Sun, W., Timko, K., McQuade, R. D., Sanchez, R., Vester‐Blokland, E., & Marcus, R. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00974.x · Cited by 63
An update on antidepressant use in bipolar depression
Sidor, M. M., & MacQueen, G. M. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0323-6 · Cited by 57
HCN Channel Targets for Novel Antidepressant Treatment
Ku, S. M., & Han, M.-H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0538-7 · Cited by 54
“LTG is often administered in conjunction with lithium to stabilize mood [237, 238].”
BackgroundSajatovic, M., Gildengers, A., Al Jurdi, R. K., Gyulai, L., Cassidy, K. A., Greenberg, R. L., Bruce, M. L., Mulsant, B. H., Ten Have, T., & Young, R. C. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00923.x · Cited by 49
Kemp, D. E., Gao, K., Fein, E. B., Chan, P. K., Conroy, C., Obral, S., Ganocy, S. J., & Calabrese, J. R. (2012) · Bipolar Disorders · doi:10.1111/bdi.12013 · Cited by 39
“A modicum of evidence also suggests that lamotrigine is efficacious for acute bipolar depression (15), including as an add-on treatment for patients non-responsive to lithium (16).”
BackgroundCurrent landscape, unmet needs, and future directions for treatment of bipolar depression
Frye, M. A., Prieto, M. L., Bobo, W. V., Kung, S., Veldic, M., Alarcon, R. D., Moore, K. M., Choi, D.-S., Biernacka, J. M., & Tye, S. J. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70005-9 · Cited by 36
Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data
Post, R. M., Goldstein, B. I., Birmaher, B., Findling, R. L., Frey, B. N., DelBello, M. P., & Miklowitz, D. J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.025 · Cited by 31
Metadata
- Authors
- van der Loos, M. L. M., Mulder, P. G. H., Hartong, E. G. T. M., Blom, M. B. J., Vergouwen, A. C., de Keyzer, H. J. U. E. M., Notten, P. J. H., Luteijn, M. L., Timmermans, M. A., Vieta, E., & Nolen, W. A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-12-30
- Volume
- 70
- Issue
- 2
- Pages
- 223-231
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2139035213
- Cited by
- 243
- References
- 0
- FWCI
- 15.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.